Novel Human IGF-I-Specific And IGF-I, IGF-II Cross-Reactive Antibodies As Potential Anti-Tumor Agents
Background:
The National Cancer Institute's Nanobiology Program is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize IGF-I-specific monoclonal antibodies.
A major drawback of current chemotherapy-based therapeutics is the
cytotoxic side-effects associated with them. Monoclonal
antibody-based therapies have taken a lead among the new cancer
therapeutic approaches with fewer side-effects.
Technology:
The type 1 insulin-like growth factor receptor (IGF1R) is
over-expressed by many tumors and mediates proliferation, motility,
and protection from apoptosis. Agents that inhibit IGF1R expression
or function can potentially block tumor growth and metastasis. Its
major ligands, IGF-I and IGF-II, are over-expressed by multiple
tumor types. Previous studies indicate that inhibition of IGF-I,
and/or IGF-II binding to its receptor negatively modulates signal
transduction through the IGF pathway and concomitant cell
proliferation and growth. Therefore, use of humanized or fully
human antibodies against IGFs represents a valid approach to
inhibit tumor growth.
The present invention describes the identification and
characterization of three novel fully human monoclonal antibodies
designated m705, m706, and m708, which are specific for
insulin-like growth factor (IGF)-I. Two of the three antibodies
(m705 and m706) are specific for IGF-I and do not cross react with
IGF-II and insulin while, m708 cross reacts with IGF-II. These
antibodies can be used to prevent binding of IGF-I and IGF-II to
the IGFIR receptor, consequently modulating diseases such as
cancer. The invention also describes methods for treating various
human diseases associated with aberrant cell growth and motility
including breast, prostate, and leukemia carcinomas.
Potential Commercial Applications/Possible
Markets Identified:
- Therapeutics for multiple types of carcinomas
Main Advantages of
Technology/Invention:
- Fully human antibodies reduce the probability for immune
responses and cytotoxic side effects
- Provides cross reacting and non-cross reacting antibodies for a
broader range of therapeutic strategies
R&D Status: Pre-clinical-in
vitro
Further R&D Needed:
- Test antibodies in animal models of cancer and in human
clinical trials
- Test antibodies in combination with other antibodies that have
been already approved for treatment, including herceptin
IP Status: U.S. Patent Application
No. 12/296,328 filed 07 Oct 2008
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel: 301-435-3121
Email: hewesj@mail.nih.gov
Please reference advertisement #866
Revised 4/16/2009